drugset / Trial / NCT03493789
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
Phase 1
Completed
19 enrolled
Emory University
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collabRefleXion Medical · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This trial studies how well fludeoxyglucose F-18 - positron emission tomography (PET) works in planning radiation therapy in participants with early non-small cell lung cancer, early stage lung cancer, or cancer that has spread to lungs from other parts of the body. Using PET in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
Timeline
- Start
- 2018-04-13
- Primary completion
- 2019-03-19
- Completion
- 2019-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | — | Intravenous |